학술논문
House dust mite subcutaneous immunotherapy has sustained long‐term effectiveness on allergic rhinitis and asthma: A 10‐year follow‐up
Document Type
article
Author
Source
Immunity, Inflammation and Disease, Vol 11, Iss 10, Pp n/a-n/a (2023)
Subject
Language
English
ISSN
2050-4527
Abstract
Abstract Background Maintenance doses for allergen immunotherapy (AIT) have been recommended for at least 3 years but little data on long‐term efficacy is available depending on AIT duration. To show sustained efficacy 10 years after completion of treatment with depigmented‐polymerized house dust mite (dpg‐pol HDM) allergen extract in adults with asthma and/or rhinoconjunctivitis. Methods Patients included in a double‐blind placebo‐controlled AIT study with dpg‐pol HDM allergen extract were reviewed at completion of the perennial treatment and 10‐year follow‐up (10y‐FU). Change in symptom and rescue medication score was the primary objective. Visual analog scale (VAS), asthma control test (ACT), and degree of disease control were the secondary objectives. A comparative analysis between patients who underwent AIT treatment for